The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

Silexion Therapeutics Corp. announced that it will present a poster at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco, scheduled for January 23-25, 2025. The presentation will focus ...

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly ...

After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...

In such individuals, known to be at increased risk of atherosclerotic cardiovascular disease (ASCVD), plozasiran at various doses conferred significantly larger reductions over placebo in fasting ...

An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...

A particular protein deficiency that leads to liver and lung damage is currently treatable only with decades-old therapies that all have limitations. Biotech startup AIRNA is part of a field of ...

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three ...

Researchers said these findings confirm that zilebesiran can significantly reduce serum angiotensinogen levels, leading to sustained reductions in blood pressure over a 24-hour period, even 6 months ...